Prof Jerry Greenfield
Research Level
Biography
Prof Greenfield is an Endocrinologist and Clinical researcher. He is Head of the Department of Endocrinology and Director, Diabetes Services, at St Vincent’s Hospital. His current positions and roles include: Professor of Medicine, University of New South Wales; Clinical Associate Dean, St Vincent’s Clinical School, University of New South Wales; Editor-in-Chief, Endocrinology, Diabetes and Metabolism Case Reports; Editorial Board member, Clinical Obesity.
He previously held an NHMRC Neil Hamilton Fairley Postdoctoral Research Fellowship, which allowed him to study in the Departments of Medicine and Clinical Biochemistry, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK (2005-6, Supervisors: Prof Stephen O’Rahilly and Dr Sadaf Farooqi). He undertook a PhD at the Garvan Institute from 2001-2004, under the supervision of Prof D Chisholm, Prof L Campbell and Prof K Samaras). He graduated from the Faculty of Medicine with Honours (class 1) from the University of NSW in 1995.
Prof Greenfield is an Endocrinologist and Clinical researcher. He is Head of the Department of Endocrinology and Director, Diabetes Services, at St Vincent’s Hospital. His current positions and roles include: Professor of Medicine, University of New South Wales; Clinical Associate Dean, St Vincent’s Clinical School, University of New South Wales; Editor-in-Chief, Endocrinology, Diabetes and Metabolism Case Reports; Editorial Board member, Clinical Obesity.
He previously held an NHMRC Neil Hamilton Fairley Postdoctoral Research Fellowship, which allowed him to study in the Departments of Medicine and Clinical Biochemistry, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK (2005-6, Supervisors: Prof Stephen O’Rahilly and Dr Sadaf Farooqi). He undertook a PhD at the Garvan Institute from 2001-2004, under the supervision of Prof D Chisholm, Prof L Campbell and Prof K Samaras). He graduated from the Faculty of Medicine with Honours (class 1) from the University of NSW in 1995.
Awards and Honours
2005 - PhD Thesis Prize, Garvan Institute of Medical Research
2001-2 - Greenfield JR. NHMRC Travelling Award for Research Training Scholarship
2001-4 - Greenfield JR. NHMRC Medical/Dental Award for Research Training (PhD)
1995 - Graduation Prize in Surgery for the best performance in the surgery component of Integrated Clinical and
Community Studies and the surgery component of integrated clinical studies 6 in course 3801 (BSc (Med) MB BS), Faculty of Medicine, University of New South Wales
1989-94 - Inaugural Alumni Association Scholarship, University of New South Wales
Education
2001 - FRACP, Endocrinology Royal Australasian College of Physicians
1995 - MBBS (Hons 1), BSc (Med), Medicine ,University of New South Wales
Selected Publications
Samocha-Bonet D, Debs S, Greenfield JR. Prevention and treatment of type 2 diabetes – a pathophysiological-based approach. Trends Endocrinol Metab 29(6):370-379 (2018). Review
Ma C, Tonks K, Center JR, Samocha-Bonet D, Greenfield JR. Complex interplay among adiposity, insulin resistance and bone health. Clin Obesity 8(2):131-139 (2018).
Kozan P, Blythe JC, Greenfield JR, Samocha-Bonet D. The effect of buffering high acid load meal with sodium bicarbonate on postprandial glucose metabolism in humans – a randomized placebo-controlled study. Nutrients 11;9. pii: E861 (2017).
Tonks KT, White C, Center J, Samocha‐Bonet D, Greenfield JR. Bone turnover is suppressed in insulin resistance, independent of adiposity. J Clin Endocrinol Metab 102 (4) 1112-1121 (2017).
Chen DL, Brown R, Liess C, Poljak A, Xu A, Zhang J, Trenell M, Jenkins AB, Chisholm DJ, Samocha-Bonet D, Macefield VG, Greenfield JR. Muscle sympathetic nerve activity is associated with liver insulin sensitivity in obese non-diabetic men. Frontiers in Physiology (Autonomic Neuroscience) 8: 101 (2017).
Tonks KT, Coster AC, Christopher MJ, Chaudhuri R, Xu A, Gagnon-Bartsch J, Chisholm DJ, James DE, Meikle PJ, Greenfield JR, Samocha-Bonet D. Skeletal muscle and plasma lipidomic signatures of insulin resistance and overweight/obesity in humans. Obesity (Silver Spring). 24: 908-16 (2016).
Lee P, Swarbrick MM, Greenfield JR. The Sum of All Browning in FGF21 Therapeutics. Cell Metab. 21: 795-5 (2015).
Lee P and Greenfield JR. Non-pharmacological and pharmacological strategies of brown adipose tissue recruitment in humans. Molecular and Cellular Endocrinology. 418 (Pt 2):184-90 (2015).
Samocha-Bonet D, Chisholm DJ, Gribble FM, Holst JJ, Greenfield JR. L-glutamine and whole protein restore first-phase insulin response and increase glucagon-like peptide-1 in type 2 diabetes patients. Nutrients. 7: 2101-8 (2015).
Lee P, Greenfield JR. What is the optimal bone-preserving strategy for patients with Addison’s disease? Clin Endocrinol (Oxf). 83: 157-61 (2015).
Kozusko K, Tsang VHM, Bottomley W, Cho YH, Gandotra S, Mimmack ML, Lim K, Isaac I, Patel S, Saudek V, O'Rahilly S, Srinivasan S, Greenfield JR, Barroso I, Campbell LV, DB Savage. Clinical and molecular characterization of a novel PLIN1 frameshift mutation identified in patients with familial partial lipodystrophy. Diabetes. 2015 64: 299-310.
Samocha-Bonet D, Chisholm DJ, Gribble FM, Coster AC, Carpenter KH, Jones GR, Holst JJ, Greenfield JR. Glycemic Effects and Safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study. PLoS One. 2014 20: e113366.
Greenfield JR, Chisholm DJ. How sweet it is: intestinal sweet taste receptors in type 2 diabetes. Diabetes 2013; 62:3336-3337.
Tonks KT, Ng Y, Miller S, Coster ACF, Samocha-Bonet D, Iseli TJ, Xu A, Patrick P, Yang JYH, Junutula JR, Modrusan Z, Kolumam G, Stöckli J, Chisholm DJ, James DE*, Greenfield JR* (*equal last authors). Impaired Akt phosphorylation in insulin-resistant human muscle is accompanied by selective and heterogeneous downstream defects. Diabetologia. 2013; 56: 875-85.
Greenfield JR, Samaras K, Campbell LV. Correspondence: Sugar-Sweetened Beverages, Genetic Risk, and Obesity. N Eng J Med 2013; 368:285-287.
Myint KS, Greenfield JR, Henning E, Farooqi IS, Holst JJ, and Finer N. Prolonged successful therapy for hyperinsulinaemic hypoglycaemia after gastric bypass: the pathophysiological role of GLP-1 and its response to a somatostatin analogue. Eur. J. Endocrinol 2012; 166: 951-955.
Samocha-Bonet D, Chisholm DJ, Tonks K, Campbell LV, Greenfield JR. Insulin-sensitive obesity in humans - a "favorable fat" phenotype? Trends Endocrinol Metab 2012; 23:116-124.
Samocha-Bonet D, Wong O, Synnott, E-S, Piyaratna N, Douglas A, Gribble FM, Holst JJ, Chisholm DJ, Greenfield JR. Glutamine reduces postprandial glycaemia and augments the GLP-1 response in type 2 diabetes patients. J Nutrition 2011; 141: 1233-1238.
Martinelli CE, Keogh JM, Greenfield JR, Henning E, van der Klaauw AA, Blackwood A, O'Rahilly S, Roelfsema F, Camacho-Hubner C, Pijl H, Farooqi IS. Obesity due to Melanocortin 4 Receptor (MC4R) deficiency is associated with increased linear growth and final height, fasting hyperinsulinemia, and incompletely suppressed Growth Hormone secretion. J Clin Endocrinol Metab 96: E181-188E (2011).
Greenfield JR. Invited review (Young Investigator Perspectives): Melanocortin signalling and the regulation of blood pressure in human obesity. Journal of Neuroendocrinology 2011; 23:186-193.
Greenfield JR, Miller JW, Keogh J, Henning E, Satterwhite JH, Cameron GS, Astruc B, Mayer JP, Brage S, See TC, Lomas DJ, O’Rahilly S, Farooqi IS. Modulation of blood pressure by central melanocortinergic pathways. N Eng J Med 2009; 360: 44 – 52.
Greenfield JR, Farooqi IS, Keogh J, Henning E, Habib A, Blackwood A, Reimann F, Holst JJ, Gribble F. Oral glutamine increases circulating GLP-1, glucagon and insulin levels in lean, obese and type 2 diabetic subjects. Am J Clin Nutr 2009; 89:1 – 8.
Greenfield JR, Tuthill A, Soos MA, Semple RK, Halsall DJ, Chaudhry A, O’Rahilly S. Severe insulin resistance due to anti-insulin antibodies: Response to plasma exchange and immunosuppressive therapy. Diabetic Med 2009; 26: 79 – 82.
Greenfield JR, Campbell LV. Role of the autonomic nervous system and neuropeptides in the development of obesity in humans. Curr Pharm Des 2008; 14: 1815 – 1820.
Greenfield JR, Samaras K, Chisholm DJ, Campbell LV. Effect of postprandial insulinemia and insulin resistance on measurement of arterial stiffness (Augmentation Index). Int J Cardiol 2007; 114: 50 – 56.
Greenfield JR, Campbell LV. Relationship between ‘inflammation’, insulin resistance and type 2 diabetes: cause and effect? Curr Diab Rev 2006; 2:195-211.
Greenfield JR, Samaras K, Hayward CS, Chisholm DJ, Campbell LV. Beneficial postprandial effect of a small amount of alcohol on diabetes and cardiovascular risk factors: Modification by insulin resistance. J Clin Endocrinol Metab 2005; 90: 661-672.
Greenfield JR, Samaras K, Jenkins AB, Kelly PJ, Spector TD, Gallimore JR, Pepys, MB, Campbell LV. Obesity is an important determinant of baseline C-reactive protein concentration in monozygotic twins, independent of genetic influences. Circulation 2004; 109:3022-3028.
Greenfield JR, Samaras K, Jenkins AB, Kelly PJ, Spector TD, Campbell LV. Moderate alcohol consumption, dietary fat composition, and abdominal obesity in women: evidence for gene-environment interaction. J Clin Endocrinol Metabol 2003; 88: 5381-5386.
Greenfield JR, Samaras K, Campbell LV, Jenkins AJ, Kelly PJ, Spector TD, Hayward CS. Physical activity reduces genetic susceptibility to increased central systolic pressure augmentation: A study of female twins. J Am Coll Cardiol 2003; 42:264-270.
Greenfield JR, Samaras K, Chisholm DJ. Insulin resistance, intra-abdominal fat, cardiovascular risk factors, and androgens in healthy young women with type 1 diabetes. J Clin Endocrinol Metab 2002; 87:1036-40.
